Our company (formerly, Interactive Capital Partners Corporation) was incorporated pursuant to the Business Corporations Act (Ontario) on April 30, 2008 under the name Interactive Capital Partners Corporation. On September 29, 2023, the Company completed a business combination (the "Business Combination") with SkinJect Inc.
Status note Next-generation GnRH antagonist; composition-of-matter patents expire 2039. APC: planned Phase 2b dose-optimization study (substantial modification application submitted via EU CTIS Jun 8, 2026). AUR: optimized Phase 2 design submitted to FDA Apr 6, 2026; FDA written feedback and central IRB approval (with modifications) received Jul 16, 2026. Endometriosis: PRECISION-E2 Phase 2a genomics-enabled trial in UAE; IND authorized by UAE DOH Jul 31, 2026.
Status note IND #139837 (CDER Oncology Division). Phase 2 SKNJCT-003 in nBCC: positive dose response from pre-specified expanded dataset analysis announced May 6, 2026. SKNJCT-005 registrational Phase 2b for Gorlin Syndrome: protocol submitted to FDA Jun 3, 2026; FDA safety review complete and 'Study May Proceed' letter issued Jul 27, 2026 authorizing initiation of NDA-enabling registrational Phase 2b.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.